gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Caelyx 20 mg/m2 q2wks in platinum-refractory or early recurrent ovarian or peritoneal cancer - results from a phase II study

Meeting Abstract

  • corresponding author presenting/speaker Monika Persing - Martin-luther-universität halle, Deutschland
  • Ursula Beau - martin-luther-universität halle
  • Nancy Kendzierski - martin-luther-universität halle
  • Ina Karbe - martin-luther-universität halle
  • Hans-Georg Strauss - martin-luther-universität halle
  • Christoph Thomssen - martin-luther-universität halle

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocPO352

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Persing et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



In this mono-institutional phase II study we investigated liposomal doxorubicin (Caelyx) 20mg/m² every two weeks in patients with ovarian or peritoneal cancer who failed a platinum based therapy or had an early recurrent disease (recurrence within six months after platinum-based therapy). Response and toxicity were evaluated especially with regard to frequency and grade of palmar-plantar erythrodysesthesia (PPE) of liposomal doxorubicin administered in a 2-week schedule. 37 patients (age 38-78) were treated. The median number of prior chemotherapy regimens was 3,1 (range 1 - 6). 14 objective responses (37.8%) were observed (3 complete and 11 partial responses). 6 patients received a stable disease. There was no hematological toxicity > G2 and only 3 G3-nonhematological toxicities. In four patients a PPE grade 2 was observed; no PPE grade 3/4 occured. Caelyx is a favourable therapeutic option in patients with platinum-refractory or early recurrent ovarian or peritoneal cancer with tolerable toxicity. In comparison with other phase II trials we found a very high response rate using Caelyx in this two-week schedule.